



INTUITIONLABS / RESEARCH & PRACTICAL GUIDANCE

A Guide to the ICH M8 eCTD v4.0 Submission Specification

Build practical AI for pharma and biotech with IntuitionLabs. We help life-science teams turn complex information and workflows into useful software, governed knowledge systems and AI tools.

Published by IntuitionLabs · 2026-01-15 · ich m8 · ectd v4.0 · hl7 rps · regulatory submissions · submission specification · regulatory affairs · ectd · pharmaceutical regulation

Original article: <https://intuitionlabs.ai/articles/ich-m8-ectd-v4-specification>



In this article

1. Executive Summary
2. Introduction
3. Background on Regulatory Submissions and ICH
4. Purpose of This Report
5. Historical Evolution of eCTD and ICH M8
6. Early Submission Formats and the CTD
7. Need for a Next-Generation Standard
8. ICH M8 eCTD v4.0 Specification – Technical Content
9. HL7 RPS and Message Structure
10. ICH M8 “Specification for Submission Formats”
11. Example Table: Key File-Format Requirements
12. Metadata and Context Groups
13. Specification Implementation Guides and Packages
14. Global Adoption Timeline
15. Implementation and Compliance
16. Tools and Validation
17. Industry and Vendor Perspective
18. Data Analysis and Key Findings
19. Comparisons: eCTD v3.2 vs v4.0
20. Case Studies and Real-World Examples
21. EU Regulatory Submission Pilot (2025)
22. FDA eCTD 4.0 Pilot (2024)
23. ICH Governance and Future Phases
24. Implications and Future Directions
25. Regulatory Impact
26. Technology and Standards Integration
27. Limitations and Challenges
28. Conclusion
29. References

Executive Summary

The **ICH M8** guideline defines the electronic Common Technical Document (eCTD) version 4.0 **submission specification**, detailing how files and metadata must be formatted for regulatory dossiers. Developed by the ICH M8 Expert Working Group (EWG) starting in 2010, this specification builds on Health-Level Seven (HL7) standards (notably the Regulated Product Submission, RPS, HL7 V3 RIM) to create a unified global message format for **electronic regulatory submissions** (www.ema.europa.eu) (www.ijdra.com). The adoption of eCTD v4.0 aims to modernize and harmonize submissions by consolidating message structures, enabling dynamic content tables and code lists, and improving interoperability across agencies.

This report provides a comprehensive, evidence-based analysis of the ICH M8 eCTD specification. It reviews the historical context and evolution of eCTD standards, the technical content of the M8 specification (including detailed file and PDF requirements), and its relationship to the new HL7-based message format. We analyze regulatory implementation timelines (regional “phase-in” of v4.0 in the US, EU, Japan, etc.), industry implications, and technology considerations (workflows, publishing tools, [validation](#)). Multiple stakeholder perspectives – regulators, industry sponsors, and vendors – are examined through case studies and pilot summaries. Key findings include:

- **Specification Content** – The M8 specification lays out strict requirements for submission files (e.g. PDF versions 1.4–1.7 or PDF/A, embedded fonts, ≤500 MB per file) and metadata (tables of contents, hyperlinks/bookmarks, context grouping) to ensure legible, searchable dossiers (www.ema.europa.eu) (www.extedo.com). It codifies best practices for PDF generation (no JavaScript or dynamic elements, text-searchable content, OCR for scanned documents) and establishes new tagging and controlled vocabulary standards inherited from HL7 RPS. Industry guidance emphasizes features like hierarchical bookmarking, unique headers, and regulatory-code metadata for efficient review (www.extedo.com) (www.pharmalex.com).
- **Technical Basis (HL7 RPS)** – eCTD v4.0 uses HL7 RPS as its core data model. Unlike eCTD v3.x (which used separate XML messages per region), the v4.0 standard defines a **single, unified XML message** in which each submission unit carries both the regional Module 1 and the ICH Modules 2–5 content (sequences and lifecycle management continue) (esubmission.ema.europa.eu) (www.ijdra.com). The specification includes an ICH implementation guide and region-specific Module 1 guides (FDA, EMA, PMDA, etc.), along with controlled-vocabulary packages (teams, product info) and computational code (schema/genericcode) (www.fda.gov) (www.fda.gov). These resources are publicly available (ICH and agency websites) and have been promulgated through Step 4 adoption by ICH (in 2015) and Step 5 implementation updates.
- **Regulatory Adoption** – Though finalized in 2015, eCTD v4.0 adoption began only in the 2020s. After a 2022–2023 technical pilot, FDA's CDER and CBER have accepted new applications in v4.0 on a voluntary basis since September 16, 2024; ICH's implementation table lists FDA mandatory use for 2029 (admin.ich.org) (www.fda.gov) (en.ennov.com). Japan completed a technical pilot in Q2 2021, accepted v4.0 voluntarily from 2022 and made it mandatory in April 2026 (admin.ich.org) (japan.freyrsolutions.com) (japan.freyrsolutions.com). The EMA announced optional use for new centralised marketing applications from Dec 22, 2025; ICH lists v4.0 as strongly recommended for new centralised MAAs from Q1 2027 and mandatory for them from Q1 2028 (esubmission.ema.europa.eu) (pharmaceuticalmanufacturer.media). Other ICH regions (Canada, China, etc.) have published guidance and regional M1 modules aligned with the ICH framework. These staggered timelines (mandatory in Japan since April 2026; announced mandates elsewhere from 2028 to 2030, with several regions still TBD) reflect industry and regulator readiness.
- **Industry Impact and Perspectives** – eCTD 4.0 is expected to streamline dossier maintenance and review, but also imposes new workflow requirements. Case studies from pilot projects indicate that **submission assembly is largely similar** to eCTD 3.2.2, but companies must learn new concepts (context grouping, keyword tagging, “priority” numbers) and update tools (www.pharmalex.com)

(en.ennov.com). Analysts note that delayed adoption is largely due to competing priorities (e.g. IDMP data standards, regulatory workload) (globalforum.diaglobal.org) (pharmaceuticalmanufacturer.media). Stakeholders stress the importance of early tool validation, cross-functional planning, and participation in pilots to ease the transition (en.ennov.com) (pharmaceuticalmanufacturer.media).

- **Future Directions** – eCTD v4.0 sets the stage for continual improvement. Forward-compatibility pilots (e.g. EMA Phase 3 tests in 2026 (esubmission.ema.europa.eu)) are underway to enable existing product lifecycles to move to v4.0. **Regulatory convergence** will continue (controlled vocabularies, code lists published periodically). The adoption of HL7 RPS also aligns with broader healthcare interoperability trends (e.g. **ICSR/Safety messaging**). Looking ahead, agencies will refine the standard and validation criteria over time, and industry must adapt to integrated data standards (IDMP, etc.) and evolving technology (cloud review systems, advanced publishing).

In sum, the ICH M8 eCTD specification is a critical foundation for next-generation electronic submissions. It codifies global technical standards to ensure consistent, quality-controlled files in regulatory applications (www.ema.europa.eu) (www.extedo.com). Our report details its content and context and provides guidance for sponsors and regulators navigating its implementation.

Introduction

Background on Regulatory Submissions and ICH

The *electronic Common Technical Document (eCTD)* is a harmonized format for submitting regulatory dossiers for pharmaceuticals (www.ema.europa.eu) (www.ijdra.com). It evolved from the *Common Technical Document (CTD)*, introduced in the late 1990s, which defined a common modular structure (Regions 1–5) for all ICH regions (US, EU, Japan) (globalforum.diaglobal.org). The eCTD overlays this structure with an electronic portal, defined originally by technical specifications in the early 2000s. Under ICH guidance (M2 and related work), agencies standardized file formats and folder structures so that applications could be submitted as an ordered set of PDF files, linked by XML "backbone" files.

The original eCTD reached its final v3.2.2 specification in 2008, with regional mandates following over the next decade (globalforum.diaglobal.org) (globalforum.diaglobal.org). In this system, each new sequence was an additional XML message (the "CTD sequence"), with a consistent table of contents. While this revolutionized dossier review (replacing paper submissions), it had limitations. Updates to content structure or metadata were cumbersome; each region had its own localized Module 1 indexes; and agencies needed multiple messages for each submission (industry often produced separate ICH and regional packages).

By the 2010s, regulators and industry agreed on a need for a *next-generation* submission standard. The US FDA pioneered this: in 2008 it began developing **Regulated Product Submissions (RPS)** – an HL7 messaging standard for regulatory data (globalforum.diaglobal.org) (www.ijdra.com). By ICH Step 4 in 2015, RPS was adopted as the basis of **eCTD version 4.0** (globalforum.diaglobal.org) (www.ijdra.com). In ICH terminology, this work is codified under **M8** (the M8 "electronic Common Technical Document" guideline). Our focus is on the ICH M8 technical specification for eCTD v4.0 ("Specification for Submission Formats for eCTD"), which prescribes file construction within this new architecture.

Purpose of This Report

This report thoroughly examines the ICH M8 eCTD specification. It begins with historical context: why a new standard was needed, and how ICH evolved the eCTD from version 3.2 to 4.0. We then delve into the technical core of M8: how HL7 RPS shapes the XML message, what code lists and controlled vocabularies are defined, and how metadata (tables of contents, context groups, keywords) are used. A separate major focus is the *Specification for Submission Formats*, which details the acceptable formats and properties of files (PDFs and other objects) in an eCTD submission – covering fonts, scanning, navigation aids and more. The interplay between ICH guidance and regional implementation (FDA, EMA, PMDA, etc.) is described.

We provide evidence-based analysis including:

- Historical evolution (with authoritative references on ICH steps and eCTD versions (www.ema.europa.eu) (globalforum.diaglobal.org)).
- Data tables summarizing key requirements and timelines.
- Citations to official guidelines (ICH/EMA/FDA documents) wherever possible.
- Case studies and pilot results illustrating industry experiences (www.pharmalex.com) (en.ennov.com).
- Statistics and statements from industry and regulatory leaders on benefits and challenges (globalforum.diaglobal.org) (pharmaceuticalmanufacturer.media).

The aim is that the reader finishes with a clear understanding of ICH M8's contents, why and how eCTD v4.0 is being implemented globally, and its implications for pharmaceutical regulation and industry practices.

Historical Evolution of eCTD and ICH M8

Early Submission Formats and the CTD

Historically, new drug applications were paper volumes. With the establishment of the CTD (late 1980s onward (globalforum.diaglobal.org)), regulators in the US, EU, and Japan could rely on a common dossier outline. The CTD had a global structure: Module 1 (region-specific administrative data), Module 2 (summaries), Modules 3–5 (quality, nonclinical, clinical) (globalforum.diaglobal.org). Importantly, Module 1 remained region-specific outside the CTD, but the other modules were harmonized.

The first electronic submissions in the 1990s used proprietary formats (e.g. XML over SGML or custom systems) and often required CDs/DVDs of scanned images. In 2003–2005, under ICH M2, regulators published the first formal **eCTD v2.0** specification. This allowed dossiers to be submitted as folder structures of PDF files, with a specially formatted XML backbone. Each application “sequence” (initial submission or subsequent update) became an additional XML, linking into a cumulative submission. The standard required PDF/A or PDF formats, defined naming rules and MD5 checksum integrity, etc. Over the next decade, incremental updates (eCTD 3.0, 3.1, 3.2, ultimately 3.2.2) were published. The final eCTD 3.2.2 spec was adopted by ICH (Step 4) in 2008 (globalforum.diaglobal.org) (www.ema.europa.eu).

Over the following years, eCTD 3.2.2 became widely implemented and, in practice, the global standard for electronic submissions. This achieved a dramatic reduction in paper and faster global reviews (www.ijdra.com) (pharmaceuticalmanufacturer.media). However, the limitation was that the eCTD's technical architecture was largely “frozen” into the XML backbone approach from 2003-05. Notably, the official **table of contents** (TOC) – the taxonomy of sections and allowables in the CTD – was difficult to modify, so subtle disparities across regions persisted. All version updates had to go through ICH processes, delaying changes.

Need for a Next-Generation Standard

Around 2010, stakeholders recognized that more flexibility and interoperability were needed. The US FDA engineers had begun a new messaging standard (HL7 RPS) to generalize regulatory exchange, akin to IDMP for product data. In 2008 FDA initiated the RPS development via the HL7 SDO (globalforum.diaglobal.org). RPS defined a domain-message model (R-MIM diagram) that could represent each regulatory submission as a structured HL7 message.

Under ICH auspices, the **M8 Expert Working Group** was formed in November 2010 (www.ema.europa.eu). Its mandate: develop the *next major version* of the eCTD, called **eCTD v4.0**. eCTD v4.0 would be fundamentally built on HL7 RPS (ISO/HL7 certified standards) (www.ijdra.com). The goal was “to facilitate the processing and review of electronic regulatory submissions” globally (www.ema.europa.eu). Key early decisions (around 2011–2012) included: single XML message for Modules 2–5, context-based metadata (keywords, priorities), and alignment with ICSR/MedicalContentMessaging.

By 2012, this work had matured: M8 produced draft “Modules 2–5 Implementation Guide”, “Backbone Files Specification”, and related documents (esubmission.ema.europa.eu). At an HL7 ballot in Jan 2012, “Regulatory Product Submission Release 2 Draft Standard for Trial Use 2” was approved (esubmission.ema.europa.eu), providing a concrete basis. In June 2012, the M8 EWG finalized key eCTDv4.0 documents (Step 2 for testing) (esubmission.ema.europa.eu). Subsequently, public consultations and revisions led to the ICH Assembly's endorsement of the Step 4 implementation package in December 2015 (www.ema.europa.eu) (globalforum.diaglobal.org).

Thus, **2015** was a milestone: eCTD v4.0 achieved ICH Step 4 (endorsement). As the Loebel article notes: “That standard [eCTD 4.0] was approved to Step 4 at ICH in 2015” (globalforum.diaglobal.org). From then on, agencies and companies began the gradual shift to the new format. eCTD v4.0 is often described as “available since 2015, but adoption has been delayed (globalforum.diaglobal.org)”.

ICH M8 eCTD v4.0 Specification – Technical Content

The **ICH M8 specification** for eCTD v4.0 is a suite of technical documents, including an Implementation Guide (IG), code lists, schema, and a separate submission format specification. It supersedes the ICH M2 specification (which covered eCTD v3.2.x). Below we break down its components and content:

HL7 RPS and Message Structure

At the core of eCTD v4.0 is the **HL7 Regulatory Product Submission (RPS)** model (www.ijdra.com) (esubmission.ema.europa.eu). The M8 specification imports HL7's R-MIM structure, which represents a submission as an XML message tree. Key features:

- **Single Message per Submission Unit:** In eCTD 3.x, each sequence combined an ICH backbone with a separate regional Module 1 XML file. In v4.0, each submission unit is described by one XML message that organises both the ICH Modules 2–5 content and the regional Module 1 content (esubmission.ema.europa.eu) (www.fda.gov). Sequences and lifecycle operations continue: each new submission unit adds to the cumulative dossier, and each region still defines its own Module 1 content and vocabularies.
- **Implementation Guides:**
 - ICH provides a **global Implementation Guide (IG)** for Modules 2–5 (i.e. the common content) (www.fda.gov).
 - Each region (FDA, EMA, PMDA, etc.) publishes its **Regional Module 1 IG** and controlled vocabularies.
 - For example, as of October 2026 FDA supports the ICH IG Package v1.6 and its own Regional Module 1 IG v1.9, while the ICH Assembly endorsed ICH IG v1.7 in June 2026 (admin.ich.org); check each agency's page for the versions it currently supports (www.fda.gov) (www.ijdra.com).
- **Controlled Vocabularies and Code Lists:** ICH defines **controlled vocabulary (CV)** packages for common regulatory metadata (product codes, dossier types, etc.) used in v4.0 messages (www.fda.gov). These ensure consistent tagging of submissions. Regions also add *regional-specific* vocabulary sets (e.g. U.S. application types, EU administrative codes).
- **XML Schemas/Genericode:** The specification includes XML Schemas (XSD) for the message, as well as Genericode files to enumerate controlled vocabularies, priorities, country lists, etc. These support machine-readable validation.
- **Backward Compatibility:** The v4.0 IG preserves much of the eCTD content (e.g. CTD module hierarchy) but implements it via RPS constructs. Legacy content is mapped into the new message format. Notably, the entire Table-of-Contents (TOC) hierarchy is no longer fixed by the core standard; ICH publishes separate ICH and regional TOC code lists so that new categories can be added more flexibly.

ICH M8 “Specification for Submission Formats”

In addition to the above, the M8 work includes a **Specification for Submission Formats**, sometimes informally called the “file format specification”. This document describes exactly *how* each file in an eCTD should be prepared. It encompasses guidelines on:

- **PDF Documents:** The standard document type for narrative content.

- **Other File Types:** Images, spreadsheets, video (though the spec generally encourages minimal use of non-PDF media).
- **Pagination and Navigation:** Page layout, numbering, bookmarks.
- **Security and Accessibility:** Encryption, text searchability, etc.

While the full M8 specification document is not publicly quoted in full, its requirements are echoed in industry guidance documents. We summarize key technical points below, citing available sources:

PDF Technical Requirements

Modern eCTD submissions require high-quality PDF files that ensure consistent appearance. Based on M8 guidance and regulatory sources (www.extedo.com) (www.extedo.com):

- **Accepted PDF Versions:** The current ICH specification defers to the PDF versions listed on ICH's M2 recommendations page (admin.ich.org); PDF 1.4 through 1.7 are commonly cited, and PDF/A acceptance varies by region, so check the applicable regional specification (www.allfordrugs.com) (www.extedo.com).
- **File Size Limit:** Typically, no single PDF file should exceed **500 MB** (www.allfordrugs.com), to prevent burden on review systems. If a document is larger, sponsors should split content into multiple logical PDFs.
- **Font Embedding:** The current ICH specification says to **embed all fonts used in the PDF**, use only OpenType or TrueType fonts and avoid customised fonts, so that text renders correctly for reviewers (admin.ich.org) (www.allfordrugs.com). As a best practice, use Times New Roman 12 pt for main text; multi-column tables or smaller text should be no smaller than ~9–10 pt.
- **Colors and Contrast:** Black text on white background is recommended. Blue may be used for hyperlinks. Avoid light font colors, pastel highlights, or background shading, as these may not print or display well (www.allfordrugs.com).
- **Page Orientation and Margins:** Pages should be upright (portrait or landscape as appropriate, but not rotated). A margin of at least **2.5 cm on the binding edge** (the left side of portrait pages, the top of landscape pages) should be provided so information is not obscured when documents are printed and bound; the remaining margins should be at least **1.0 cm** (admin.ich.org) (www.allfordrugs.com). Header and footer information and page numbers should not appear in the margins.
- **Header/Footer Content:** Each page should include a unique header or footer indicating document identity (title, form identifier, section, etc.) so that pages can be distinguished even if removed from context (www.allfordrugs.com).
- **Security Settings:** PDFs should not be password-protected to open. If security settings restrict editing, the receiver must still be able to open, view, extract form data, print, and copy text, images and other content (admin.ich.org).

Scanned Documents and Images

The specification and regulatory guidance emphasize **minimizing scanned pages** (www.allfordrugs.com) (www.extedo.com), because OCR is required for text searchability:

- If original electronic version exists, use that; avoid printing and rescanning.
- **If scanning is necessary** (handwritten forms, older lab notebooks, etc.), scan at **≥ 300 dots per inch (dpi)** in black-and-white. Use grayscale or color *only if needed* (grayscale can drastically increase file size) (www.allfordrugs.com).
- Ensure scanned text is made **OCR-searchable** where possible. After OCR, verify accuracy carefully – automated text conversion can introduce errors (www.extedo.com).
- **High-resolution graphics** (e.g. chromatography traces) should be at least 300 dpi. Black ink (or dark blue) is recommended for hand-written annotations (≥ 300 –600 dpi) (www.allfordrugs.com).

Regulators strongly prefer electronic originals with text embedded. If scanned PDF must be used, it should be OCR'd and checked so that text can be searched (www.extedo.com).

Document Structure and Navigation

eCTD v4.0 supports enhanced navigation aids for reviewers. The format specification recommends:

- **Bookmarks (Outline):** Bookmarks are expected even when a document has no table of contents, and a hypertext-linked TOC plus bookmarks should be included in documents of 5 pages or longer (admin.ich.org). Typically up to 4 levels of nested headings are allowed, though study reports may have deeper outlines (www.allfordrugs.com). On opening, bookmarks should be *collapsed to the first level* by default.
- **Hyperlinks:** In-document hyperlinks (cross-references) should use relative file paths, so they remain valid if moved between drives (www.allfordrugs.com). Hyperlinks can be indicated by blue text or a visible rectangle.
- **Pagination:** Number pages sequentially per document, starting at 1. Do *not* use Roman numerals anywhere. If a large document is split into parts (e.g. multiple PDFs), continue numbering across parts (Page N continues to N+1) to preserve order (www.allfordrugs.com).
- **Selective PDF Forms or 3D:** No multimedia (video, embedded 3D, audio) or active scripts are allowed. Dynamic content, attachments and 3D content must be avoided, and PDF annotations should not be included except in Annotated Case Report Forms (admin.ich.org) (www.extedo.com).
- **Accessibility:** While not always mandated for eCTD, PDFs should ideally comply with basic accessibility: logical reading order, alt-text for images, etc. Many agencies encourage bookmarking and searchable text for ease of review (www.extedo.com).

Other File Formats and Metadata

While most content in an eCTD is PDF, other file types can be included (subject to rules):

- **Spreadsheets** (XLS/XLSX) may be submitted for raw data or tables if needed (some regulators discourage them). If used, they should have clear headers and be readable without macros. Standardised study datasets follow agency-specific rules instead (for FDA, SAS Transport .xpt files per

its study data guidance and Data Standards Catalog); do not substitute CSV for them.

- **Image Files** (JPEG, TIFF) should be of high resolution if included. Color space should be sRGB, and resolution ≥ 300 dpi for critical images. Lossless TIFF is often recommended; JPEG may be used for photos if compression is gentle (no more than 10:1).
- **Study Data and XML Metadata:** Tabular study data (SDTM, SEND, ADaM) and their XML metadata (e.g. Define-XML) are distinct file types governed by each agency's study-data requirements (for FDA, its Study Data Technical Conformance Guide and Data Standards Catalog) and are validated separately from the eCTD package.
- **Naming Conventions:** The M8 spec expects all files to have unique names within the dossier, typically matching the sections of the table of contents. Long names and special characters are discouraged; only basic ASCII alphanumeric, underscores, and hyphens.

Significantly, the **M8 specification emphasizes self-validation**. Applicants should “validate the quality of the renditions” (www.allfordrugs.com), using validation tools (agency validators, eSUB checkers) before submission. The specification itself will be enforced by agency validation rules (see Section on Validation Tools below).

Example Table: Key File-Format Requirements

The following table summarizes major file-format requirements conveyed by ICH M8 and related guidelines:

Requirement	Details	Source(s)
PDF Versions	Versions per ICH M2 recommendations (commonly 1.4–1.7); PDF/A acceptance varies by region.	(www.extedo.com)
Max PDF Size	≤ 500 MB per file.	(www.allfordrugs.com) (ICH M8 spec)
Fonts	Embed all fonts; use standard fonts (Times New Roman, Arial, Courier). 12-pt Times NR for text.	(www.allfordrugs.com)
Font Color	Black text recommended; blue for hyperlinks. Avoid faint colors or shadows.	(www.allfordrugs.com)
Page Orientation	Page up (portrait/landscape as designed); no rotations.	(www.allfordrugs.com)
Margins	≥ 2.5 cm on binding edge; ≥ 1.0 cm on others (ICH specification v1.3).	(www.allfordrugs.com)
Page Numbering	Arabic numerals only, sequential. No Roman numerals.	(www.allfordrugs.com)
Bookmarks/TOC	Bookmarks expected; linked TOC plus bookmarks for documents of 5+ pages; ≤ 4 levels recommended. Bookmarks collapsed on open.	(www.allfordrugs.com)
Hyperlinks	Use relative paths for intra-document links. Highlight (color/box).	(www.allfordrugs.com)
Security	No open password; any editing restrictions must still allow viewing, printing, copying and form-data extraction.	(www.allfordrugs.com)
Multimedia	No JavaScript, dynamic content (audio, video), attachments or 3D; no annotations except Annotated CRFs.	(www.extedo.com) (www.extedo.com)

Requirement	Details	Source(s)
Text Searchability	All text must be searchable. OCR and correct scanned docs if used.	(www.extedo.com)
Scanning	Avoid scanning; if used, scan ≥ 300 dpi BW, use OCR. Black ink handwriting (≥ 300 dpi).	(www.allfordrugs.com) (www.extedo.com)
Document Quality	Avoid blurry or pixelated images. Use vector definitions (charts) where possible.	(General best practice)
ToC Labels/Headers	Include brief subject info (e.g., doc title) in header/footer.	(www.allfordrugs.com)

Table 1. Major file-format requirements in the ICH M8 eCTD v4.0 specification (derived from ICH/EU/US FDA guidance). Some items (bold) come directly from the specification; others reflect common industry practice per regulators (www.extedo.com) (www.allfordrugs.com) (www.extedo.com).

Metadata and Context Groups

A distinguishing feature of eCTD v4.0 is the use of explicit XML *metadata* to describe each document. The M8 specification defines elements like:

- **Context of Use:** Each document is placed in the dossier through a context of use, coded against the ICH (or regional) controlled vocabulary that represents the CTD table-of-contents headings. Contexts of use that share the same code and keywords form a context group (admin.ich.org).
- **Keywords:** Keywords qualify a context of use (for example the drug substance, manufacturer or indication a document relates to). Some keyword types use ICH or regional controlled vocabularies; others are sender-defined through a keyword definition included in the submission.
- **Priority Number:** Each context of use carries a priority number that sets the display order of documents within the same context group.

These metadata elements enable software to verify and rebuild the folder structure, and allow reviewers to filter or navigate by keyword. The use of code lists and context groups is specified in the controlled vocabulary packages (the ICH eCTD v4.0 Controlled Vocabulary Package and the regional packages).

Specification Implementation Guides and Packages

The **ICH eCTD v4.0 Implementation Package** (often versioned separately, e.g. v1.5) contains all the components needed to implement the new standard. Its contents include:

- **Implementation Guide (IG)** (Modules 2–5). Specifies document types, metadata usage, file referencing rules, and examples.
- **vocabulary/generate** files: ISO-structured code lists.

- **XML Schema (XSD)** files, and example “packages”.
- **Support Documentation** (post-Step 4 orientations, FAQs, Q&A).
- **Validation Criteria:** Agency-specific validation rules (FDA) and ICH eCTD validation rule sets.

Each region augments this with:

- **Regional Module 1 IG** (e.g. FDA eCTD v4.0 M1 IG v1.5 (www.fda.gov), EMA IG M1, PMDA IG M1, Health Canada IG M1).
- **Regional Controlled Vocabularies** for Module 1 fields (like application types).
- **Domain-specific guidance** (e.g. FDA also published a Technical Conformance Guide for eCTD v4.0 (www.fda.gov)).

The FDA **eCTD v4.0 Technical Conformance Guide** (TCG) version 1.4 (Sep 2022) is a key document in the US. It reincorporates ICH rules and adds FDA specifics. Similarly, Health Canada has issued (in-proposal or draft) versions of its Module 1 Technical Implementation Guide.

Through these materials, sponsors learn how to compile a v4.0 submission. The paradox is that for good content, an eCTD v4.0 submission closely resembles a v3.2.2 submission. The main differences lie in how metadata are embedded and how the files are assembled in the XML. In fact, early industry feedback (e.g. EU pilots) suggests the practical *compilation process* is only modestly different (www.pharmalex.com). Instead, the heavy lifting has gone into defining and harmonizing the standard.

Global Adoption Timeline

Despite finalization in 2015, eCTD v4.0 has had a slow rollout worldwide. Figure 1 (below) outlines key milestones by region:

Date	Region	Event	Source
June 2012	ICH (M8 Step 2)	ICH M8 EWG completes draft eCTD v4.0 Modules 2–5 for testing (HL7 RPS base).	(esubmission.ema.europa.eu)
March 2015	ICH (Global)	eCTD v4.0 Implementation Guide (M8 IG v2.0 draft) published for consultation (ICH Step 2).	(www.ema.europa.eu)
2008–2012	FDA / HL7	FDA initiates HL7 RPS development (2008); an HL7 ballot approves RPS Release 2 as a Draft Standard for Trial Use (Jan 2012).	(globalforum.diaglobal.org)
2015 (Dec)	ICH	ICH Assembly endorses the eCTD v4.0 Step 4 implementation package (RPS-based standard).	(www.ijdra.com) (admin.ich.org)
2022–2023	FDA	FDA runs its eCTD v4.0 technical pilot (completed Q2 2023).	(admin.ich.org) (www.fda.gov)
		(Note: FDA's site lists CDER/CBER accepting eCTD4 from 9/16/2024)	(www.fda.gov)
Sep 2024	US (FDA)	CDER and CBER begin voluntary acceptance of new applications in eCTD v4.0.	(www.fda.gov) (en.ennov.com)

Date	Region	Event	Source
2021–2022	Japan (PMDA)	Technical pilot completed Q2 2021; voluntary acceptance from 2022.	(admin.ich.org) (japan.freyrsolutions.com) (japan.freyrsolutions.com)
Dec 22, 2025	EU (EMA)	EMA announces optional use of eCTD v4.0 for new CAP MAA from 22 Dec 2025.	(esubmission.ema.europa.eu)
2026–2028	EU (EMA)	Forward-compatibility pilot (Phase 3) under way in 2026; v4.0 strongly recommended for new CAP MAAs from Q1 2027 and mandatory from Q1 2028.	(esubmission.ema.europa.eu) (admin.ich.org)
Apr 2026	Japan (PMDA)	eCTD v4.0 becomes mandatory.	(japan.freyrsolutions.com) (admin.ich.org)
2028–2030	Global	Planned mandates per ICH (Aug 2026): EU new CAP MAAs Q1 2028; FDA 2029; Health Canada and Swissmedic 2030; Brazil, Korea and Australia TBD.	(pharmaceuticalmanufacturer.media) (japan.freyrsolutions.com)

Figure 1: Key milestones in global eCTD v4.0 adoption (historical and projected). Note voluntary use began in Japan in 2022 and in the US in 2024, with the EU following in late 2025 for optional use ([www.fda.gov](#)) ([esubmission.ema.europa.eu](#)). Mandatory dates vary by region, from April 2026 (Japan) to 2030 (Canada, Switzerland) ([japan.freyrsolutions.com](#)) ([pharmaceuticalmanufacturer.media](#)).

United States (FDA): The FDA's page confirms that “CDER and CBER are accepting new regulatory applications in eCTD v4.0 format as of September 16, 2024.” ([www.fda.gov](#)). This followed a 2022–2023 technical pilot. FDA's own standards page sets no mandatory date for v4.0, and FDA has said it will give advance notice; ICH's August 2026 implementation table lists FDA mandatory use for 2029 ([admin.ich.org](#)). The FDA's eCTD v4.0 Submissions Standards page lists the relevant IGs and tools. Ennov reported in September 2024 that a large global pharma client had successfully submitted multiple eCTD v4.0 sequences during the pilot scheme ([en.ennov.com](#)).

European Union (EMA): The EMA announced that, from 22 December 2025, applicants *may* optionally submit new MAAs (CAPs) in eCTD v4.0 ([esubmission.ema.europa.eu](#)). During this opt-in period, v3.2.2 remains fully accepted. EMA emphasizes that companies must coordinate with the agency and ensure their tools meet the published validation criteria and vocabularies ([esubmission.ema.europa.eu](#)). EMA has also published draft EU validation criteria (opened for comment) and new controlled vocabularies (v3) in late 2025 ([esubmission.ema.europa.eu](#)). A Phase 3 pilot on "forward compatibility" (moving existing 3.2.2 dossiers to v4.0) has been running in 2026, and ICH lists v4.0 as strongly recommended for new centralised MAAs from Q1 2027 and mandatory for them from Q1 2028 ([admin.ich.org](#)) ([esubmission.ema.europa.eu](#)). The **European eCTD v4 implementation guide (M1)** and validation criteria are being updated in parallel.

Japan (PMDA): Japan completed its eCTD v4.0 technical pilot in Q2 2021 and began voluntary acceptance in 2022 ([admin.ich.org](#)) ([www.pmda.go.jp](#)). Use of v4.0 became mandatory in April 2026 ([japan.freyrsolutions.com](#)). PMDA provides its own Module 1 Implementation Guide (v1.5 was published in Feb 2023 and later versions have followed ([www.ijdra.com](#))) and updates to Japanese vocabulary tables.

Other Regions: Health Canada published a draft Canadian M1 IG (2019) (www.ijdra.com), indicating intent to align with eCTD v4.0. ICH's August 2026 table lists Health Canada voluntary use from 2028 and mandatory use in 2030, Swissmedic voluntary use from 2027 and mandatory use in 2030, and Brazil, Korea and Australia with mandatory dates still TBD (admin.ich.org). Because eCTD v4.0 is an ICH harmonized standard, all participating regulatory agencies coordinate its adoption.

As of October 2026, v4.0 is mandatory in Japan and optional in the US and for new EU centralised MAAs; the other announced mandates fall between Q1 2028 (EU, new centralised MAAs) and 2030 (Canada, Switzerland) (admin.ich.org) (pharmaceuticalmanufacturer.media) (japan.freyrsolutions.com). Companies must track individual agency timelines closely.

Implementation and Compliance

Tools and Validation

Implementing eCTD v4.0 requires supporting tools and validators. Major eCTD publishing software vendors (e.g. Lorenz, Extedo, Ennov) have been adding eCTD v4.0 support to their platforms. Regulatory agencies and third parties provide **validation tools** to check conformance:

- **FDA eCTD v4.0 TCG:** FDA's Technical Conformance Guide (v1.5, July 2026) specifies submission scenarios, folder structure conventions, and agency-specific checks (www.fda.gov). The FDA ESG is the transmission channel; FDA lists Lorenz eValidator, applying its eCTD v4.0 validation criteria, as the tool for eCTD v4.0 packages, while Pinnacle 21 Enterprise validates standardised study data (SDTM, SEND, ADaM). The FDA site lists the current versions of validation schemas and rules.
- **EMA Validation Rules:** EMA uses a set of XML schemas and business rules to validate submissions. During pilot phases, regulated companies reported using vendor tools (e.g. Lorenz's eValidator) to pre-check package structures (www.fda.gov) (www.pharmalex.com).
- **Submission gateways:** Electronic Submission Gateways (FDA ESG, EMA's eSubmission Gateway, PMDA Gateway) will enforce format rules. Agencies typically do not process out-of-spec submissions.

Notably, many of the guidelines (bookmarks, attachments, etc.) are recommendations rather than strict requirements; however, major issues like invalid XML or missing required metadata result in outright rejection.

Industry and Vendor Perspective

Company Workflows: Interviews and articles from industry highlight that formatting a dossier under eCTD 4.0 is similar to 3.2.2 in many respects (www.pharmalex.com) (en.ennov.com). The eCTD v4.0 messages still contain PDF attachments per CTD Section. The learning curve is in assigning context keys, using the new XML wrappers, and ensuring completeness of schema metadata. Companies must update internal publishing workflows:

- **Content Tagging:** Sponsors need to tag documents with the new ICH/agency codes (context and keywords). This often requires data mapping from legacy CTD numberings to the new code list values. Pharmaceutical regulatory information management (RIM) systems are adapting to store these metadata.
- **Tools Integration:** Content Management Systems (CMS) or Document Management Systems (DMS) must integrate with the eCTD-publishing tool to generate v4 packages. Some organizations face challenges in “round-tripping” content between systems (especially for large companies that share work across departments or CROs) (www.pharmalex.com).
- **Validation:** Early adopters stress the importance of early validation. Performing full pilot submissions and validating them (with agency or third-party tools) is advised to catch formatting issues beforehand (en.ennov.com).

Vendor Feedback: Regulatory software providers report both eagerness and caution. Software firms like Ennov encourage client participation in agency pilots to gain firsthand experience (en.ennov.com). ArisGlobal notes that maintaining and tuning tools for HL7 complexity is non-trivial, but it opens the door to future interoperability with other healthcare data standards (pharmaceuticalmanufacturer.media).

Case Study: EU Technical Pilot (2025)

In 2025, EMA and industry ran a “**Technical Pilot**” for eCTD 4.0 involving multiple companies and software vendors (www.pharmalex.com). Key observations from participants:

- *Compilation Ease:* General consensus was that producing an eCTD 4.0 dossier was **similar to 3.2.2**. The fundamental steps of gathering PDFs per module and tagging a submission pack did not change dramatically.
- *New Challenges:* The main hurdles identified were:
- **Context/Keywords:** Learning to select the correct context codes for each document’s place in the TOC, and to assign any applicable keywords/priorities.
- **Tool Differences:** Different publishing platforms had varying user interfaces for eCTD4 metadata, so experiences varied by vendor (www.pharmalex.com).
- **System Integration:** Ensuring the internal content management workflows (e.g. how LIMS data or Hive Trace files get converted and linked) worked within v4 was highlighted as a project task.
- *Forward Compatibility:* Forward compatibility (continuing an existing 3.2.2 lifecycle in v4.0) was left to the next pilot step; companies must still plan how ongoing 3.2 → 4.0 transitions will work, especially for products already under review (www.pharmalex.com).
- *Outcome:* Overall, participants became more comfortable with the format. PharmaLex’s Karl-Heinz Loebel noted that the pilot allowed the agency to “assess differences between software vendors and determine what can and can’t be accommodated” (www.pharmalex.com).

This case shows that by giving industry hands-on practice, both regulators and companies identify practical issues (e.g. UI training, additional guidelines needed) before full roll-out.

Case Study: FDA Pilot (2024)

In the US, FDA ran a technical pilot in 2022–2023 ([admin.ich.org](https://www.fda.gov/oc/2023/09/16/fda-announces-technical-pilot-for-e-ctd-v4-0)) and began voluntary production acceptance of v4.0 for new applications on September 16, 2024. For example, an Ennov blog recounts that a major global pharma successfully submitted **multiple eCTD v4.0 sequences** during FDA's initial pilot phase ([en.ennov.com](https://www.ennov.com)). This suggests that at least some tools and processes could already produce packages FDA accepted in the pilot, although one vendor's account does not establish general conformance. The blog emphasizes preparation (company & vendor collaboration) as critical for pilot readiness ([en.ennov.com](https://www.ennov.com)). The Ennov team even hosted events to train sponsors on the v4.0 pilot. Their summary of pros/cons suggests that engaging in the pilot allows companies to provide feedback, build confidence, and develop new internal processes for eCTD4 (housekeeping new templates, checks, version control) ([en.ennov.com](https://www.ennov.com)).

Industry Concerns

Despite technical readiness, some industry analysts have voiced caution about rapid eCTD4 migration. For instance, opinions circulated (“Just Say No” on LinkedIn) questioning the benefits given the investment required. PharmaLex and ArisGlobal responses counter that viewpoint, stressing that indefinite delay is riskier. An ArisGlobal executive notes that **by 2026–2029 new regulations will enforce eCTD 4.0**; companies delaying preparation risk being unable to file on time ([pharmaceuticalmanufacturer.media](https://www.pharmaceuticalmanufacturer.media)). Moreover, eCTD 4.0 compliance offers long-term gains: a single standard across regions, more reusable submission content (IDs and tags can be updated outside the core IG), and better data consistency. The main trade-off is up-front cost in IT adjustments and staff training, versus smoother regulatory submissions in the future.

Data Analysis and Key Findings

Collecting “hard data” on eCTD 4.0 is challenging because adoption is recent. However, the following points are evidence-based:

- **Global Reach of eCTD (all versions)** – Data from ICH/EU/FDA show eCTD is ubiquitous. The ArisGlobal article notes that eCTD (through 3.x) is “widely accepted by markets including EU, UK, US, Canada, several Middle East countries, Asia Pacific, as well as Australia, and South Africa” ([pharmaceuticalmanufacturer.media](https://www.pharmaceuticalmanufacturer.media)). In practice, virtually all mature regulatory agencies in pharma require or accept eCTD (or an equivalent electronic dossier) for new submissions. The move to v4.0 thus affects almost all global product registrations.
- **Time to Adoption** – The ICH target was that eCTD 4.0 would “facilitate” submissions and reduce processing time (www.ema.europa.eu). However, actual uptake has been slow. A 2024 analysis points out that *10 years after Step 4 (2015), only Japan and the US had implemented eCTD 4.0 in any way* ([globalforum.diaglobal.org](https://www.globalforum.diaglobal.org)). In other words, FY2025 is still part of the transition, not the stable state. The delayed adoption is partly substantiated by lack of large-scale v4.0 filing statistics – agencies have only just begun to track eCTD v4.0 usage (and may publish numbers later).
- **Practical Concerns** – Industry commentary (not published pilot error statistics) points to areas needing attention:

- Misassigned context codes (documents placed in wrong module/section).
- Missing hyperlink or bookmark structure.
- Files outside allowed PDF/A versions.
- Forward compatibility issues in continuing an existing CTD lifecycle. These reflect the new spec's areas of emphasis. Agencies will likely publish aggregated feed-back if pilots conclude.
- **Case-study Outcomes** – Though anecdotal, pilot experiences share consistency. For example, in the EMA pilot, PharmaLex reported that the main challenges were keywords, context groups and priority numbers, plus minor glitches in some tools (www.pharmalex.com). This suggests the specification is workable, although tools still varied. However, regulators highlighted validation criteria that needed refinement (leading to EMA's 2025 draft updated criteria (esubmission.ema.europa.eu)).

Comparisons: eCTD v3.2 vs v4.0

To clarify changes, we compare key aspects of legacy eCTD (M2) and new eCTD (M8):

Aspect	eCTD v3.2 (Old Standard)	eCTD v4.0 (M8 Specification)
Core Format	Sequences, each with an ICH backbone (index.xml) plus a separate regional Module 1 XML (www.fda.gov)	One XML message per submission unit covering ICH and regional content, based on HL7 RPS; sequences and lifecycle continue (esubmission.ema.europa.eu) (www.ijdra.com)
Message Basis	ICH XML backbone DTD, style sheets	HL7 RPS R-MIM schema (ISO/HL7) (www.ijdra.com)
Module 1	Region-specific (ICH XML + local DTD)	Region-specific but integrated into RPS message; separate IGs
Controlled Vocabularies	Static TOC (CTD Index), region lists	ICH-controlled vocabularies, continuously updatable; generic code formats
Flexibility	TOC hierarchical structure largely fixed	Context-based grouping allows ad hoc content addition; dynamic sections
Forward Compatibility	Not explicitly supported	Designed to handle lifecycle continuations (planned pilot phase)
XML Syntax	ICH DTD-based XML backbone (e.g. leaf elements)	HL7 RPS-based XML (e.g. context of use, keywords, priority numbers)
Data Models	CTD specific to drug dossiers	RPS model applicable to any regulated product submission
File Types	Primarily PDF; limited attachments	Primarily PDF; similar rules but integrated as SLA content in XML
Processes (change management)	Change requests via ICH (slow)	Easier updates via HL7 standards, and Regions can adjust M1 content lists.

Table 2. Comparison of eCTD v3.2 vs eCTD v4.0 (as defined by ICH M2 vs M8). eCTD v4.0 is built on HL7 RPS and offers greater flexibility and standardization across regions (www.ijdra.com) (pharmaceuticalmanufacturer.media). The table is a high-level summary; many details (e.g. exact XML syntax) are specified in the IGs.

Case Studies and Real-World Examples

EU Regulatory Submission Pilot (2025)

In 2025, EMA conducted a **technical pilot** (phase 2) for eCTD v4.0, involving numerous pharma companies and vendors (www.pharmalex.com). Participants prepared mock submissions for Marketing Authorisations (initial MAAs, generics, etc.). Outcomes included:

- **Minimal Compilation Changes:** Applicants noted *few differences* in how they compiled dossiers. The navigation enhancements (keywords, context, priorities) were largely familiar to modern eCTD tools (www.pharmalex.com).
- **Metadata Learning Curve:** Companies struggled initially with new concepts. Assigning "keywords" (document attributes) and maintaining "priority" values (for sort order) proved to be new tasks (www.pharmalex.com).
- **Vendor Tool Variance:** Differences were seen between software from different vendors. Some tools had better interfaces for building the new XML, or for managing controlled vocabularies.
- **Forward Compatibility:** The pilot also explored converting an ongoing eCTD 3 life-cycle into 4.0. This raised questions on how to transition a partially reviewed product (requiring continued updates in the new format).
- **Regulatory Perspective:** EMA scientists used the pilot to compare vendor outputs. They reported that **industry tool results varied**, so validating tools for conformance was important, and possibly issuing informal guidance on best practices.

This real-world pilot (learnings summarized by PharmaLex) shows that while eCTD v4.0 adds technical requirements (and has a learning curve), many industry experts feel the practical burden is manageable. It was also noted that adoption of v4.0 by users required corporate strategy (especially to manage vocabulary consistency) rather than a fundamental technology overhaul (pharmaceuticalmanufacturer.media).

FDA eCTD 4.0 Pilot (2024)

FDA's technical pilot ran from 2022 to Q2 2023 (admin.ich.org), and voluntary production acceptance began in September 2024. Ennov reports that at least one large global pharmaceutical company submitted test sequences. Details gleaned from industry blogs:

- A large pharma submitted "multiple eCTD 4.0 sequences" during the pilot (en.ennov.com). Their positive outcome suggests that the submission went through the FDA Gateway without major technical errors.
- An industry regulator blog (Ennov) recommends that sponsors engage their tech vendors early, as regulatory requirements in v4.0 are new to everyone (en.ennov.com).
- The FDA's public messaging (on acceptance from Sept 16, 2024) indicates the pilot allows for both ICH-wide and US-specific submissions. (For example, the FDA's eCTD page lists "ICH eCTD v4.0 Implementation Guide" and "FDA Regional v4.0 Module 1 Guide" packages (www.fda.gov) (www.fda.gov), implying test use of both global and US regional documents.)

While no detailed public report of the FDA pilot is available yet, industry commentary echoes the EU experience: the biggest practical task is aligning internal processes. The Ennov blog highlights that testers in the pilot are checking that their “business processes are working” alongside the technical file format (en.ennov.com).

ICH Governance and Future Phases

The pilot programs (EU and FDA) are in effect final Stage 2/3 of the ICH Step execution: after Step 4 approval, Step 5 involves implementation by members. Current ICH M8 implementation work includes:

- Collecting user feedback from national pilots.
- Refining the IG and validation rules (as seen in EMA drafts & FDA TCG updates).
- Ensuring global support infrastructure (vocabulary maintenance, product support).

One innovative aspect is the **forward compatibility** pilot. Because many drugs have existing eCTD 3.2 dossiers, agencies must allow those projects to continue in v4.0 without losing data. EMA's Phase 3 pilot, running in 2026, is testing exactly that (esubmission.ema.europa.eu). It is akin to a case study where a mid-stream drug development project moves to v4.0 mid-way.

Implications and Future Directions

Regulatory Impact

Adoption of ICH M8 eCTD specification will have widespread implications for regulatory review:

- **Harmonization:** A single, HL7-based format removes many region-specific quirks. In principle, reviewers in different countries will see dossiers structured identically except for Module 1. Cross-border reliance and work-sharing may become easier because files are interoperable. EMA emphasizes that eCTD v4.0 provides “greater interoperability with global regulatory authorities” (esubmission.ema.europa.eu).
- **Efficiency:** Automated indexing, richer metadata, and better search/bookmark navigation promise to accelerate review. Agencies anticipate more efficient lifecycle tracking (changes to submissions, tagging impactful differences) than in the older format.
- **Maintenance:** For ongoing regulatory work, the ability to modify the TOC and vocabularies by code-list rather than by issuing a new version of the entire spec is valuable. As one industry analyst noted, eCTD v4.0 allows *dynamic* management of allowed content lists, addressing a long-standing inflexibility (globalforum.diaglobal.org).
- **Compliance Burden:** In the near term, regulatory ops teams must update procedures. New training for reviewers will be needed, since many have only worked with v3.x format. Agencies like FDA have begun internal training and system upgrades for their review platforms.
- **Industry Readiness:** Companies must align their systems and processes as well. According to Agnes Cwieneczek of ArisGlobal, writing in September 2023, preparing for eCTD 4.0 is a **strategic priority**; otherwise submissions could be rejected once mandates take effect

([pharmaceuticalmanufacturer.media](#)). She warns that many companies are currently focused on IDMP (product identification) and risk overlooking the dossier standard, which can critically delay approvals ([pharmaceuticalmanufacturer.media](#)).

Technology and Standards Integration

The choice of HL7 RPS links eCTD 4.0 to a broader ecosystem of health IT standards. Potential synergies include:

- **Information Exchange:** RPS aligns with other HL7 standards (e.g. Clinical Document Architecture, FHIR). In the future, regulatory submission data could integrate more smoothly with clinical trial record systems, safety databases (ICSRs), and national health data.
- **IDMP and Beyond:** The ICH M8 standard dovetails with the ISO IDMP standards for product data. The common use of controlled vocabularies (like substance identifiers) means sponsors can potentially re-use data sets across submission content and product master data. However, experts note that organizations must plan “consistent vocabularies, keywords and content tagging” across IDMP and eCTD initiatives ([pharmaceuticalmanufacturer.media](#)).
- **Automation and AI:** The richer metadata of eCTD 4.0 could facilitate new technologies. For example, AI-driven document review or automated quality checks rely on structured inputs (keywords, context codes). In the long term, one can envision algorithmic scrutiny of dossier completeness or automated workflows triggered by metadata (e.g. alert if a key signature page is missing).
- **Future versions:** ICH continues to evolve the standard. Agencies will periodically update validation criteria and code lists. The de-coupling of the core standard logic (IG) from specific allowed content means smaller updates (e.g. new work-sharing descriptors) can be published electronically without restarting the rate-limiting ICH Step process.

Limitations and Challenges

The transition to eCTD 4.0 is not without issues:

- **Legacy Data Integration:** Converting or integrating existing eCTD 3.2 submissions requires care. The concept of “backward compatibility” is being explored but is inherently complex. In practice, most products will maintain dual processes: older data under 3.2 and new data in 4.0 during transition.
- **Tool Compatibility Variance:** As seen in EU pilots, not all publishing tools performed identically. This could cause inconsistent submissions unless vendors coordinate standards interpretation. Regulators may need to enforce stricter conformance (push tool vendors to align).
- **Staff Training and Expertise:** Regulatory professionals (both industry and agency) must learn the new format. The steepness of the learning curve varies by role: eCTD specialists will adapt quicker than occasional users.
- **IDMP and Resource Competition:** Many regulators and companies are simultaneously working on ISO IDMP implementation and other mandates. As noted in industry sources, eCTD 4.0 might be deprioritized vis-à-vis these projects, which could slow adoption ([globalforum.diaglobal.org](#)) ([pharmaceuticalmanufacturer.media](#)).

- **File Quality Control:** The specification lays out robust guidelines (see Table 1), but compliance in practice depends on publisher diligence. Experience with eCTD 3.x shows common failings (e.g. unsearchable text, no bookmarks) still crop up. Continued emphasis on quality assurance will be necessary.

Conclusion

The ICH M8 eCTD specification represents a **major leap in regulatory technology**. It codifies a modern, harmonized approach for electronic submissions, building on global health data standards. This report has outlined its historical roots, technical details, and real-world implications. Key takeaways:

- *M8 eCTD v4.0 is fundamentally an XML message standard (HL7 RPS) with clear file-format rules.* The specification defines both how to **structure the content** (context grouping, code lists, controlled vocabularies) and how to **format the files** (PDF/A, fonts, bookmarks, OCR). By rigorously following these rules, sponsors enable regulators to process submissions more efficiently (www.ema.europa.eu) (www.extedo.com).
- *Adoption is underway but ongoing.* The US, EU, and Japan have all taken steps to pilot and begin accepting eCTD 4.0. Japan has required it since April 2026; other announced mandates run from 2028 to 2030 (www.fda.gov) (esubmission.ema.europa.eu). Stakeholders must coordinate with regulators and use updated validation guidance as each region releases new criteria.
- *Multiple perspectives converge on the need to prepare.* Case studies show that while the new format is workable, sponsors must update tools and processes. Analysts and consultants strongly recommend active participation in pilots, cross-functional planning, and not delaying action (en.ennov.com) (pharmaceuticalmanufacturer.media). The benefits (harmonization, better data management) are expected to accrue once the transition is complete.
- *Continued evolution:* eCTD 4.0 is not the terminus. ICH and agencies will refine the standard, vocabulary, and guidance. As healthcare data standards advance, eCTD will likely integrate further with other electronic labeling (RPL), safety reporting (ICSR), and digital health initiatives.

For pharmaceutical regulators and industry alike, the ICH M8 specification is a transformative upgrade. Thorough understanding of its content and proactive engagement in implementation will be essential. This report's detailed analysis, case studies, and references provides stakeholders with the evidence-based foundation to navigate the eCTD v4.0 transition.

References

- International Conference on Harmonisation (ICH), "Electronic common technical document v4.0 – Draft ICH implementation guide v2.0, Step 2 (2015)" (www.ema.europa.eu).
- European Medicines Agency (EMA), "eCTD v4.0 Implementation Guide Package v1.6 – ICH eCTD v4.0 (Modules 2–5)", EMA eSubmission Projects.
- U.S. FDA, *eCTD Submission Standards for eCTD v3.2.2 and 4.0*, FDA.gov (2021–2025) (www.fda.gov) (www.fda.gov).

- Sudesamithiran N., “A Review on Next Generation eCTD – eCTD v4.0”, *Int. J. Drug Reg. Affairs*, 11(4):67–73, 2023 (www.ijdra.com).
- Loebel K.-H., “eCTD v4.0: A Look at 2025 and Beyond”, *DIA Global Forum*, May 2025 (globalforum.diaglobal.org) (globalforum.diaglobal.org).
- Crasto A.M., “ICH M8 Specification for Submission Formats for eCTD”, *All About Drugs/NDA Blog*, May 17, 2016 (www.allfordrugs.com).
- Extedo, “PDF requirements for US FDA eCTD submissions”, Extedo Blog (2020) (www.extedo.com) (www.extedo.com).
- Ennov, “Preparing for eCTD 4.0 Pilots”, Regulatory Blog, Sep 18, 2024 (en.ennov.com) (en.ennov.com).
- PharmaLex (Loebel), “Key takeaways from the eCTD 4.0 EU technical pilot”, PharmaLex Blog, Oct 2, 2025 (www.pharmalex.com).
- ArisGlobal (Agnes Cwieneczek), “Beyond IDMP – Act Now to Reap the Benefits of eCTD 4.0 Compliance”, *Pharmaceutical Manufacturer*, 26 Sep 2023 (pharmaceuticalmanufacturer.media) (pharmaceuticalmanufacturer.media).
- Freyr Solutions, “Overview on eCTD v4.0 submission to PMDA Japan”, FAQ (2025) (japan.freyrsolutions.com) (japan.freyrsolutions.com).
- EMA eSubmission News, “Go-live announcement for EU eCTD v4.0 optional use for CAPs MAA – 15 Dec 2025” (esubmission.ema.europa.eu).
- EMA eSubmission News, “Phase 3 Pilot - Forward Compatibility (Oct 2025)” (esubmission.ema.europa.eu).
- FDA eCTD v4.0 Technical Conformance Guide (v1.5, July 2026) and eCTD Q&A guidance.
- ICH, “Specification for Submission Formats for eCTD” v1.3 (June 2021) (admin.ich.org).
- ICH, “Electronic Common Technical Document (eCTD) v4.0” implementation page (updated Aug 2026) (admin.ich.org).
- ICH E6/E8/E9 guidelines (context on CTD; general background).
- Additional sources as cited in text (ICH/Q&A, vendor whitepapers, etc.).

Source links

Links cited in this article, in order of first appearance. Full addresses are provided for readers using extracted text.

1. <https://intuitionlabs.ai/articles/veeva-vault-rim-vs-qualitydocs>
2. <https://www.ema.europa.eu/en/ich-m8-electronic-common-technical-document-ectd-v40-draft-ich-implementation-guide-v20-scientific-guideline>
3. <https://www.ijdra.com/index.php/journal/article/view/633>
4. <https://intuitionlabs.ai/articles/fda-csa-guidance-pharma>
5. <https://www.extedo.com/blog/pdf-requirements-for-us-fda-ectd-submissions>
6. <https://www.pharmalex.com/thought-leadership/blogs/key-takeaways-from-the-ectd-4-0-eu-technical-pilot/>
7. https://esubmission.ema.europa.eu/eCTD%20NMV/eCTD_NMV.htm
8. <https://www.fda.gov/drugs/electronic-regulatory-submission-and-review/ectd-submission-standards-ectd-v40-and-regional-m1>
9. <https://admin.ich.org/page/ich-electronic-common-technical-document-ectd-v40>
10. <https://en.ennov.com/blog/regulatory-blog/preparing-for-ectd-4-0-pilots/>

11. <https://japan.freyrsolutions.com/freyr-japan-pmda-ectd-v4-0-submissions-services-and-solutions>
12. https://esubmission.ema.europa.eu/eCTD%20NMV/eCTD.html?hss_channel=lcp-265525
13. <https://pharmaceuticalmanufacturer.media/pharmaceutical-industry-insights/latest-pharmaceutical-manufacturing-industry-insights/beyond-idmp-%E2%80%93-act-now-to-reap-the-benefits-of-ectd-4-0-compl/>
14. <https://globalforum.diaglobal.org/issue/may-2025/ectd-v4-0-a-look-at-2025-and-beyond/>
15. <https://intuitionlabs.ai/articles/dscsa-vs-eu-fmd-serialization-traceability>
16. <https://intuitionlabs.ai/articles/e2b-r3-icsr-reporting-standard>
17. <https://globalforum.diaglobal.org/issue/july-2024/how-did-we-get-here-a-history-of-ectd-and-prospects-for-ectd-4-0/>
18. <https://www.ema.europa.eu/en/ich-m2-electronic-common-technical-document-ectd-scientific-guideline>
19. https://admin.ich.org/sites/default/files/inline-files/Specification_for_Submission_Formats_for_eCTD_v1_3.pdf
20. <https://www.allfordrugs.com/2016/05/17/ich-m8-specification-for-submission-formats-for-ectd/>
21. <https://www.pmda.go.jp/int-activities/int-harmony/ich/0106.html>
22. <https://www.fda.gov/drugs/electronic-regulatory-submission-and-review/ectd-submission-standards-ectd-v322-and-regional-m1>

THE PUBLISHER

About IntuitionLabs

IntuitionLabs is an AI consulting, custom software development and data engineering firm serving pharmaceutical, biotechnology, medical-device and other life-science organizations. We work with clinical, regulatory, medical-affairs, commercial, quality and IT teams to connect technology decisions with the work people need to accomplish.

AI consulting and adoption

Our AI enablement services cover readiness assessments, use-case selection, governance and policies, team workshops, adoption measurement and ongoing advisory support. We help organizations structure the information layer behind AI: source material, context, permissions and maintained knowledge that make generated answers useful and reviewable. Private LLM inference and hosted AI options support teams evaluating how to operate AI with appropriate control over their data and infrastructure.

Software, data and life-science workflows

IntuitionLabs develops custom software for pharma and biotech, integrates enterprise systems, and builds data engineering and business intelligence solutions. Areas of focus include AI agents, regulatory research, medical writing, medical affairs, CMC information, competitive intelligence and clinical-document workflows. Our eTMF intelligence work includes cross-system reconciliation and inspection-readiness support.

Enterprise platforms and regulated delivery

We provide Veeva services, application support, managed services, integrations and custom applications, alongside enterprise content work involving platforms such as Egnyte. For regulated workflows, our services include GxP enablement, computer-system validation and software development addressing 21 CFR Part 11 requirements. The applicable controls, validation responsibilities and acceptance criteria are defined for each engagement.

Work with IntuitionLabs

Explore [AI enablement](#), [pharma and biotech software development](#), [data engineering and BI](#), and [Veeva services](#). [Contact IntuitionLabs](#) to discuss your workflow, information sources and implementation needs.

IntuitionLabs publishes educational research to help life-science teams make informed technology decisions. Coverage of a product or organization does not imply a client relationship, endorsement or partnership.

Website: <https://intuitionlabs.ai>

This article is educational. Verify consequential medical, legal, financial, regulatory and technical decisions with appropriate professionals and the cited primary sources. Company services are described separately from the article's research findings.